BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35971938)

  • 1. In-bore MR prostate biopsy - initial experience.
    Rembak-Szynkiewicz J; Wojcieszek P; Hebda A; Mazgaj P; Badziński A; Stasik-Pres G; Chmielik E; Bobek-Billewicz B
    Endokrynol Pol; 2022; 73(4):712-724. PubMed ID: 35971938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central zone lesions on magnetic resonance imaging: Should we be concerned?
    Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
    Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR
    BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
    Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
    World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
    Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
    BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
    Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
    Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interreader Agreement of Prostate Imaging Reporting and Data System Version 2 Using an In-Bore MRI-Guided Prostate Biopsy Cohort: A Single Institution's Initial Experience.
    Glazer DI; Mayo-Smith WW; Sainani NI; Sadow CA; Vangel MG; Tempany CM; Dunne RM
    AJR Am J Roentgenol; 2017 Sep; 209(3):W145-W151. PubMed ID: 28657843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
    Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3.0-T MR-guided transgluteal in-bore-targeted prostate biopsy under local anesthesia in patients without rectal access: a single-institute experience and review of literature.
    Bera K; Ramaiya N; Paspulati RM; Nakamoto D; Tirumani SH
    Abdom Radiol (NY); 2024 Apr; 49(4):1223-1230. PubMed ID: 38383816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
    Chen F; Cen S; Palmer S
    Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer.
    Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S
    World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer.
    Venderink W; van der Leest M; van Luijtelaar A; van de Ven WJM; Fütterer JJ; Sedelaar JPM; Huisman HJ
    World J Urol; 2017 Dec; 35(12):1849-1855. PubMed ID: 28871396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
    Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
    AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
    [No Abstract]   [Full Text] [Related]  

  • 15. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
    Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
    Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy.
    Boesen L; Noergaard N; Chabanova E; Logager V; Balslev I; Mikines K; Thomsen HS
    Scand J Urol; 2015 Feb; 49(1):25-34. PubMed ID: 24922550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer.
    Quentin M; Boschheidgen M; Radtke JP; Spohn F; Ullrich T; Drewes L; Valentin B; Lakes J; Al-Monajjed ; Arsov C; Esposito I; Albers P; Antoch G; Schimmöller L
    Eur J Radiol; 2024 Jun; 175():111436. PubMed ID: 38522396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anterior Localization of Prostate Cancer Suspicious Lesions in 1,161 Patients Undergoing Magnetic Resonance Imaging/Ultrasound Fusion Guided Targeted Biopsies.
    Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Preisser F; Tilki D; Fisch M; Graefen M; Budäus L
    J Urol; 2018 Nov; 200(5):1035-1040. PubMed ID: 29935274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score.
    Osses DF; van Asten JJ; Kieft GJ; Tijsterman JD
    World J Urol; 2017 Feb; 35(2):207-212. PubMed ID: 27287889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of Sampling PI-RADS 4-5 Index Lesions Alone by MRI-guided In-bore Biopsy in Biopsy-naive Patients Undergoing Radical Prostatectomy.
    Kilic M; Vural M; Coskun B; Acar Ö; Saglican Y; Akpek S; Esen T
    Eur Urol Focus; 2020 Mar; 6(2):249-254. PubMed ID: 31054811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.